Real-world treatment patterns and outcomes in HER2-low, HR+ metastatic breast cancer patients previously treated with endocrine therapy in the United States

Background: Up to 60% of metastatic breast cancer (mBC) cases historically classified as human epidermal growth factor receptor 2 (HER2)-negative may be HER2-low, expanding options towards new HER2 targeted treatments. Greater understanding of the current therapeutic journey of this population can h...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Shanu Modi, Danalyn Byng, Suyuan Zhang, Yan Xiong, Shannon Hunter, Kyle Dunton, Tara Harding, William Jacot
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Elsevier 2026-04-01
سلاسل:	Breast
الموضوعات:	Metastatic breast cancer Real-world evidence HER2-Low HR+ Trastuzumab deruxtecan
الوصول للمادة أونلاين:	http://www.sciencedirect.com/science/article/pii/S0960977626000317
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!